U3-1402

patritumab deruxtecan · Daiichi Sankyo Co., Ltd.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for U3-1402, covering 2024-08-13 to 2026-03-05. Get the full timeline:

Most recent: Clinical Trial Update: U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer [Phase 1]